Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Twist Bioscience insider Paula Green filed a Form 144 to sell up to 16,739 shares of common stock through Fidelity Brokerage Services LLC on or around 02/17/2026 on NASDAQ, with an aggregate market value of 877,123.60.
The notice shows these shares against a baseline of 61,311,704 common shares outstanding. The securities to be sold were mainly acquired through restricted stock vesting and one employee stock purchase plan transaction between 09/19/2024 and 02/20/2025, generally as compensation.
The filing also lists prior sales by Paula Green over the past three months, totaling 2,942 common shares on several dates, for combined gross proceeds of 109,727.69. By signing, the seller represents having no undisclosed material adverse information about Twist Bioscience’s operations.
A person associated with symbol TWST has filed a Form 144 notice to sell 22,665 shares of common stock. The planned sale, through Fidelity Brokerage Services LLC on NASDAQ, has an aggregate market value of $1,187,646.00 and an approximate sale date of 02/17/2026.
The filing lists 61,311,704 shares outstanding for this class of common stock; this is a baseline figure, not the amount being sold. The notice also discloses prior sales over the past three months by the same person, consistent with Rule 144 reporting requirements.
Twist Bioscience insider Patrick Finn filed a notice of proposed sale of 68,967 shares of the company’s common stock under Rule 144. The shares have an aggregate market value of $3,562,414.66 and are to be sold through Fidelity Brokerage Services LLC on NASDAQ.
The filing notes that 61,311,704 shares of common stock were outstanding, providing context for the planned sale. It also lists how Finn acquired these securities over time, including option grants and exercises, restricted stock vesting, and employee stock purchase plan participation, as well as his common stock sales in the prior three months.
Twist Bioscience Corp’s President and COO Patrick John Finn reported option exercises and share sales in a pre-planned trading program. On February 12 and 13, 2026, he exercised multiple stock options for common stock at exercise prices of $23.33 and $26.66 per share, converting them into ordinary shares. Over the same two days, he sold 3,500 and 1,750 shares of common stock in open-market transactions at weighted average prices of about $50.225 and $50.041 per share, with individual sale prices ranging from $50.00 to $50.51. All transactions were executed under a Rule 10b5-1 trading plan adopted on May 13, 2025, and he held 306,250 common shares directly after the reported trades, along with remaining vested stock options.
EdgePoint Investment Group Inc. reported a significant ownership position in Twist Bioscience Corp common stock. As of December 31, 2025, EdgePoint beneficially owned 5,377,991 shares, representing 8.80% of the outstanding common stock.
EdgePoint, an investment adviser based in Ontario, Canada, has sole voting and dispositive power over 4,165,651 shares and shared voting and dispositive power over 1,212,340 shares. The stake is held in the ordinary course of business and not for the purpose of changing or influencing control of Twist Bioscience.
Twist Bioscience Corporation has filed a prospectus supplement registering up to 632,328 shares of common stock for resale by existing selling securityholders. These shares are issuable under Stock Purchase Agreements dated February 11, 2026, and may be sold over time in various types of negotiated or market transactions.
The selling securityholders, including Invenra Inc. and other smaller holders, will receive all proceeds from any share sales, while Twist will receive no proceeds from these resales and will only cover registration-related expenses. The company’s common stock trades on the Nasdaq Global Select Market under the symbol TWST.
Twist Bioscience Corporation entered into stock purchase agreements with Invenra Inc. and two of Invenra’s investors. Twist will issue up to 632,328 shares of common stock. Up to 324,558 shares plus $5 million in cash will be provided to Invenra in exchange for a license agreement and certain technology. Twist will also issue up to 307,770 shares to two Invenra investors in exchange for preferred stock, giving Twist approximately a 6% ownership stake in Invenra. Twist gains the right to designate one director to Invenra’s board, whose members, including the Twist designee, may approve two additional directors. The company simultaneously granted registration rights and is filing a prospectus supplement to register the resale of these shares.
Twist Bioscience chief financial officer Adam Laponis sold 7,000 shares of common stock in an open-market transaction at $50 per share on February 12, 2026. After this planned sale under a previously adopted Rule 10b5-1 trading plan, he directly holds 130,031 shares.
Patrick Finn has filed a notice of proposed sale of restricted securities, indicating an intent to sell 1,750 shares of common stock of TWST through Fidelity Brokerage Services LLC. The planned sale, listed for 02/13/2026 on NASDAQ, has an aggregate market value of 87572.02. Shares of the issuer outstanding were 61,311,704 at the time referenced.
The shares to be sold were recently acquired through option exercises dated 11/19/2018 and 10/24/2019 (settled on 02/13/2026) totaling 1,212 shares for cash, and 538 shares from restricted stock vesting on 11/05/2024 as compensation. Over the past three months, Finn has already sold multiple common stock blocks, including 23,279 shares for gross proceeds of 931160.00 on 01/13/2026 and 3,500 shares for 175789.05 on 02/12/2026.
Twist Bioscience Corp executive Dennis Cho reported an open-market sale of company stock. On February 11, 2026, he sold 5,000 shares of common stock at a price of $49.93 per share. After this transaction, he directly owned 138,581 shares.
The filing notes that this sale was carried out under a Rule 10b5-1 trading plan that Cho had previously adopted on May 7, 2025. He serves as Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience, indicating the transaction involves a senior member of management.